Autres langues Vector Science and Therapeutics Corp.

Actions

PAIN

CA92244M1041

Sociétés holdings

Marché Fermé - Toronto S.E. 21:59:59 21/08/2026			Varia. 5j.	Varia. 1 janv.
1,830 ^CAD	+2,81%		-16,06%	+3 560,00%

20/08	Vector Science and Therapeutics Corp dépose une demande de brevet provisoire pour une plateforme intégrée de régénération des tissus orthopédiques par peptides	CI
17/08	Vector Science and Therapeutics signe un accord de fabrication et de test amendé de 10 ans	MT

Autres langues

20/08	Vector Science and Therapeutics Corp. (TSXV: PAIN) Files Provisional Patent Application on Integrated Platform for Orthopedic Tissue Regeneration Using Peptides
20/08	Vector Science and Therapeutics Corp Files Provisional Patent Application on Integrated Platform for Orthopedic Tissue Regeneration Using Peptides
19/08	/C O R R E C T I O N -- Vector Sciences & Therapeutics/
17/08	Vector Science and Therapeutics Signs Amended 10-Year Manufacturing and Testing Agreement
17/08	Vector Science and Therapeutics Corp. Signs Amended, 10-Year Manufacturing and Testing Agreement with LyoGenesis Holdings
17/08	Vector Science and Therapeutics Corp. Signs Amended, 10-Year Manufacturing and Testing Agreement With LyoGenesis Holdings LLC
28/07	Vector Science & Therapeutics Corp., LyoGenesis Plus 1, LLC And Wynn Pharmaceuticals LLC Announce Strategic Collaboration To Develop And Manufacture Critical Care Medical Products
27/07	Vector Science & Therapeutics Reports First Quarterly Financial Results as a Public Company; Announces Inaugural Investor Q&A on July 28
25/07	Vector Science & Therapeutics Reports First Quarterly Financial Results as a Public Company; Announces Inaugural Investor Q&A on July 28
24/07	Vector Science and Therapeutics Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended May 31, 2026
21/07	Vector Science to Build Distributor Network For Peptide Portfolio Commercialization
21/07	Vector Science & Therapeutics Announces Distributor Network Buildout to Support Its Peptide Portfolio Across Orthopedic, Sports, and Regenerative Medicine Channels
17/07	Vector Science & Therapeutics Corp. and Caresyntax Enters Strategic Partnership for Real-World Evidence Program for Vectormist
17/07	Vector Science & Therapeutics Partners with Surgical Intelligence Company Caresyntax
17/07	Vector Science & Therapeutics and Caresyntax Announce Real-World Evidence Partnership for VectorMist
15/07	Vector Science & Therapeutics Expands Intellectual Property Portfolio with 15 Patent Applications Around Precision Therapeutic Delivery
15/07	Vector Science & Therapeutics Builds 15-Patent-Application Intellectual Property Portfolio Around Precision Therapeutic Delivery, Anchored by Peptide and Biologic Administration Technologies
08/07	Vector Science and Therapeutics Corp. Appoints Darryl Drake Jr. as President of Valor and Chairman of the Athletic Board
07/07	Vector Science & Therapeutics Corp. Enters Exclusive Licensing and Manufacturing Agreement With LyoGenesis Plus
07/07	Vector Science & Therapeutics Announces Landmark Exclusive cGMP Manufacturing Agreement with LyoGenesis Plus for Its Proprietary Peptide Portfolio
30/06	Vector Science & Therapeutics Files Provisional Patent for Wearable Transdermal Peptide Delivery Platform
30/06	Vector Science & Therapeutics Files Provisional Patent for Breakthrough Transdermal Peptide Delivery Platform
22/06	Gary Payton II Named Chief Athletic Ambassador of Valor
15/06	Vector Science & Therapeutics Names Dexter Fowler as Chief Athletic Officer for Its Valor Platform
12/06	Vector Science & Therapeutics Names Dexter Fowler as Chief Athletic Officer for Its Valor Platform